A hormone involved in circadian timing. Formulation, timing and the sleep problem being studied all matter.
The body produces melatonin in response to darkness. Supplemental melatonin has been studied for specific sleep and circadian problems. Results from delayed sleep-wake phase disorder should not be generalized to all insomnia.
Evidence differs by sleep condition, formulation, timing and population. No overall benefit rating is assigned.
Assessment belongs to each claim and outcome. An article’s editorial status is not a grade of a substance’s safety or efficacy.Endogenous melatonin participates in circadian timing. Light exposure and timing belong in the interpretation of sleep outcomes. [3]
Descriptions of experience in their reported context. Direction does not imply benefit, and these observations do not define a universal intensity score.
Daytime sleepiness was among reported adverse events; its rate was similar between trial groups. [2]
What the research measured, for whom, and under which exposure. Findings remain attached to the study’s task or clinical endpoint.
Sleep began earlier with melatonin plus scheduling in the selected circadian-disorder population. [2]
Published exposure records, distinguished by source category. These describe study or reference context and are not personal dosing recommendations.
0.5 mg [2]
Given 1 hour before desired bedtime, with behavioral scheduling, over 4 weeks. A specific trial protocol, not general insomnia guidance.
Absorption, metabolism and elimination depend on the analyte, route, formulation, physiology and other exposures.
Approximate summary estimate in a human pharmacokinetic review, not a universal range. Release formulation and population matter. [1]
The modeled analyte is Melatonin. The curve begins after absorption and distribution; it does not predict onset, felt effects, or an individual’s response.
Route: Oral. Formulation: Immediate-release products in a heterogeneous review. Population: Human participants across reviewed studies.
Approximate summary estimate in a human pharmacokinetic review, not a universal range. Release formulation and population matter. Source & context
Approximate estimate: 0.75 hours.
The model uses this single reported estimate; no range is inferred.
Model: fraction remaining = 2−time / half-life. Assumes a single exposure, instantaneous distribution, and a constant half-life for Melatonin. Formation of metabolites, repeated exposure, and interactions are not modeled. Source & context
0.75 hoursApproximate estimate [1]
Approximate summary estimate in a human pharmacokinetic review, not a universal range. Release formulation and population matter.
The immediate-release kinetic summary should not be applied directly to prolonged-release products. [1]
Related observationAdverse effects, interactions, tolerance and withdrawal in the cited contexts. This section is not an exhaustive interaction checker.
The cited trial did not establish long-term benefit or safety, nor benefit in people without the studied circadian delay. [2]
Supplement contents can differ from labels. Evidence and safety considerations are different in children and pregnancy. [3]
The source, the finding and its limitations. Funding information is reported where curated; an unassessed disclosure does not mean a study had no commercial funding.
Summarizes exposure and large differences between formulations and study conditions.
Limitations Heterogeneous studies; an approximate central value is not a personal prediction.
Funding / disclosures Not assessed; consult the original disclosure.
Melatonin with scheduling improved sleep initiation in a selected circadian-disorder population.
Limitations Scheduling was part of treatment; long-term outcomes and broader insomnia populations were not established.
Funding / disclosures Not assessed; consult the original disclosure.
Explains circadian signaling, differences between sleep conditions and supplement quality concerns.
Limitations Public information, not individual clinical advice; year indicates access.
Funding / disclosures Not assessed; consult the original disclosure.
Source for molecular identity, formula, molecular weight and the structure diagram.
Limitations A compound record does not establish a product's purity, identity or clinical benefit.
Funding / disclosures Public database maintained by NCBI.
Each relationship retains its participants, roles and context. Shared membership does not imply that substances should be combined.
Selected delayed sleep–wake phase disorder patients receiving fast-release melatonin with scheduling.
Limitation The protocol does not establish efficacy for all insomnia or long-term treatment.
Evidence strength: not formally assessed.
Physiology summarized by NIH.
Limitation Supplement effects depend on timing, condition and formulation.
Evidence strength: not formally assessed.
Not assessed. Absence of a legal record is not a statement of legal status.
This article is a sourced draft. Editorial review has not been recorded. Content date: Sep 29, 2026.